Streetbeat News

EOLS

Evolus, Inc.

https://www.evolus.com

Industry

Drug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Evolus (NASDAQ:EOLS) and maintained a $27 price target.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 10:38 am

Evolus' dermal filler Evolysse Lift has met its primary endpoint, demonstrating superiority to Restylane-L at 6 months and showing statistically significant improvement in nasolabial fold severity compared to Restylane-L at all timepoints over 12 months.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:31 pm

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Evolus (NASDAQ:EOLS), maintaining a $27 price target.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 7:10 pm

Needham analyst Serge Belanger has reiterated a Buy rating on Evolus (NASDAQ:EOLS), maintaining a $22 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:53 am

Evolus (NASDAQ:EOLS) reported Q1 2024 earnings with an adjusted EPS of $(0.08), surpassing the $(0.10) estimate, and sales of $59.333M, exceeding the $57.321M forecast. This represents a significant improvement over the previous year, with a 46.67% decrease in losses per share and a 42.21% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 8:39 pm

Evolus, Inc. (NASDAQ:EOLS) announced the publication of Phase 2 study results in the Aesthetic Surgery Journal, demonstrating the safety and 6-month duration of effect of its 'extra-strength' 40U Jeuveau formulation for treating moderate to severe glabellar lines. The study, which compared Jeuveau 40U against two active controls (BOTOX 20U and Jeuveau 20U), showed a similar safety profile across all groups, with the majority of adverse events being mild and no serious adverse events reported. This data was presented at the 2023 ASDS Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:13 pm

Needham analyst Serge Belanger has reiterated a Buy rating on Evolus (NASDAQ:EOLS), maintaining a $22 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 10:47 am

In Thursday's after-market session, several healthcare stocks showed significant movement. Biolase, Terns Pharma, Aptevo Therapeutics, Nexalin Technology, Evolus, and Phio Pharma were among the gainers, with Biolase leading by a 20% increase following their Q4 earnings release. On the downside, Cutera, Hyperfine, China SXT Pharmaceuticals, Vicarious Surgical, Meihua Intl Medical Techs, and Assure Holdings experienced declines, with Cutera dropping 11.7% after their Q4 earnings announcement.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 9:33 pm

Evolus announced the pricing of a $50M offering of common stock, with an option for underwriters to purchase up to an additional 533,100 shares. The offering is expected to close around March 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:03 am

Stifel analyst Annabel Samimy has reiterated a Buy rating on Evolus (NASDAQ:EOLS) and increased the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 3:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.